Dynavax Technologies Corp
DVAX
查看详细走势图
15.380USD
+4.250+38.19%
收盘 12/24, 13:00（美东）报价延迟15分钟
1.81B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+38.19%
5天
+42.54%
1月
+34.44%
6月
+55.20%
今年开始到现在
+20.44%
1年
+19.78%
查看详细走势图
TradingKey Dynavax Technologies Corp股票评分
单位: USD 更新时间: 2025-12-24操作建议
Dynavax Technologies Corp当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名3/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价20.75。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Dynavax Technologies Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
4
位分析师
买入
评级
20.750
目标均价
+89.15%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Dynavax Technologies Corp亮点
亮点风险
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
业绩转盈
公司业绩转盈，最新年度盈利美元
估值低估
公司最新PE估值-42.28，处于3年历史低位
机构加仓
最新机构持股115.83M股，环比增加0.06%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值2.10K
Dynavax Technologies Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Dynavax Technologies Corp简介
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
公司代码DVAX
公司Dynavax Technologies Corp
CEOSpencer (Ryan)
网址https://www.dynavax.com/
常见问题
Dynavax Technologies Corp(DVAX)的当前股价是多少？
Dynavax Technologies Corp(DVAX)的当前股价是 15.380。
Dynavax Technologies Corp的股票代码是什么？
Dynavax Technologies Corp的股票代码是DVAX。
Dynavax Technologies Corp股票的52周最高点是多少？
Dynavax Technologies Corp股票的52周最高点是14.630。
Dynavax Technologies Corp股票的52周最低点是多少？
Dynavax Technologies Corp股票的52周最低点是9.200。
Dynavax Technologies Corp的市值是多少？
Dynavax Technologies Corp的市值是1.81B。
Dynavax Technologies Corp的净利润是多少？
Dynavax Technologies Corp的净利润为27.31M。
现在Dynavax Technologies Corp(DVAX)的股票是买入、持有还是卖出？
根据分析师评级，Dynavax Technologies Corp(DVAX)的总体评级为买入，目标价格为20.750。
Dynavax Technologies Corp(DVAX)股票的每股收益（EPS TTM）是多少
Dynavax Technologies Corp(DVAX)股票的每股收益（EPS TTM）是-0.364。
相关品种
